TUL01101
Modify Date: 2024-07-18 20:10:30
TUL01101 structure
|
Common Name | TUL01101 | ||
|---|---|---|---|---|
| CAS Number | 2411222-97-2 | Molecular Weight | 429.46 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H25F2N5O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TUL01101TUL01101 is a potent, selective and orally active JAK1 inhibitor, with an IC50s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. TUL01101 can be used for the research of rheumatoid arthritis[1]. |
| Name | TUL01101 |
|---|
| Description | TUL01101 is a potent, selective and orally active JAK1 inhibitor, with an IC50s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. TUL01101 can be used for the research of rheumatoid arthritis[1]. |
|---|---|
| Related Catalog | |
| Target |
JAK1:3 nM (IC50) JAK2:37 nM (IC50) JAK3:1517 nM (IC50) Tyk2:36 nM (IC50) |
| In Vitro | TUL01101 (pretreatment for 1 h) inhibits cytokine-induced pSTAT in human whole blood assay[1]. |
| In Vivo | TUL01101 (1-30 mg/kg; p.o. twice daily for 14 d) inhibits rheumatoid arthritis in the rat adjuvant-induced arthritis (AIA) model[1]. TUL01101 (15 mg/kg; p.o. twice daily for 14 d) inhibits rheumatoid arthritis in collagen-induced arthritis models[1]. TUL01101 (15 mg/kg; p.o.) exhibits T1/2 of 2.01 h, Cmax of 5105 nM, and oral bioavailability of 38.1% in mice[1]. TUL01101 (10 mg/kg; p.o.) exhibits T1/2 of 3.06 h, Cmax of 4965 nM, and oral bioavailability of 121% in rats[1]. TUL01101 (5 mg/kg; p.o.) exhibits T1/2 of 4.49 h, Cmax of 2750 nM, and oral bioavailability of 106.5% in dogs[1]. Animal Model: Rat adjuvant-induced arthritis (AIA) model[1] Dosage: 1, 3, 10, 30 mg/kg Administration: Orally administered twice daily for 14 days Result: Decreased the incidence in a dose-dependent manner. |
| References |
| Molecular Formula | C22H25F2N5O2 |
|---|---|
| Molecular Weight | 429.46 |